

# Remdesivir for Covid-19 pneumonia in patients with severe chronic kidney disease: Case series and review of the literature

Ahmad Al Bishawi<sup>1</sup>, Hamad Abdel Hadi<sup>1</sup>, Eman Elmekaty<sup>1</sup>, Musaed Al Samawi<sup>1</sup>, Arun Nair<sup>1</sup>, mohamed aboukamar<sup>1</sup>, Muna AlMaslamani<sup>2</sup>, and Alaaeldin Abdelmajid<sup>3</sup>

<sup>1</sup>Hamad Medical Corporation

<sup>2</sup>Hamad Medical Corp

<sup>3</sup>Hamad General Hospital

January 3, 2022

## Abstract

Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.

## Hosted file

Remdesivir\_-\_Final- Submitted.docx available at <https://authorea.com/users/438539/articles/551402-remdesivir-for-covid-19-pneumonia-in-patients-with-severe-chronic-kidney-disease-case-series-and-review-of-the-literature>